Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3